Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Global Hereditary Angioedema Therapeutics Market Outlook
4.1. Market Size & Forecast
4.1.1. By Value
4.2. Market Share & Forecast
4.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
4.2.3. By Application (Prophylaxis, On-demand)
4.2.4. By Region
4.2.5. By Company (2022)
4.3. Market Map
4.3.1. By Drug Class
4.3.2. By Distribution Channel
4.3.3. By Application
4.3.4. By Region
5. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class
5.2.2. By Distribution Channel
5.2.3. By Application
5.2.4. By Country
5.3. Asia Pacific: Country Analysis
5.3.1. China Hereditary Angioedema Therapeutics Market Outlook
5.3.1.1. Market Size & Forecast
5.3.1.1.1. By Value
5.3.1.2. Market Share & Forecast
5.3.1.2.1. By Drug Class
5.3.1.2.2. By Distribution Channel
5.3.1.2.3. By Application
5.3.2. India Hereditary Angioedema Therapeutics Market Outlook
5.3.2.1. Market Size & Forecast
5.3.2.1.1. By Value
5.3.2.2. Market Share & Forecast
5.3.2.2.1. By Drug Class
5.3.2.2.2. By Distribution Channel
5.3.2.2.3. By Application
5.3.3. Australia Hereditary Angioedema Therapeutics Market Outlook
5.3.3.1. Market Size & Forecast
5.3.3.1.1. By Value
5.3.3.2. Market Share & Forecast
5.3.3.2.1. By Drug Class
5.3.3.2.2. By Distribution Channel
5.3.3.2.3. By Application
5.3.4. Japan Hereditary Angioedema Therapeutics Market Outlook
5.3.4.1. Market Size & Forecast
5.3.4.1.1. By Value
5.3.4.2. Market Share & Forecast
5.3.4.2.1. By Drug Class
5.3.4.2.2. By Distribution Channel
5.3.4.2.3. By Application
5.3.5. South Korea Hereditary Angioedema Therapeutics Market Outlook
5.3.5.1. Market Size & Forecast
5.3.5.1.1. By Value
5.3.5.2. Market Share & Forecast
5.3.5.2.1. By Drug Class
5.3.5.2.2. By Distribution Channel
5.3.5.2.3. By Application
6. Europe Hereditary Angioedema Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Distribution Channel
6.2.3. By Application
6.2.4. By Country
6.3. Europe: Country Analysis
6.3.1. France Hereditary Angioedema Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Distribution Channel
6.3.1.2.3. By Application
6.3.2. Germany Hereditary Angioedema Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Distribution Channel
6.3.2.2.3. By Application
6.3.3. Spain Hereditary Angioedema Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Distribution Channel
6.3.3.2.3. By Application
6.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. By Drug Class
6.3.4.2.2. By Distribution Channel
6.3.4.2.3. By Application
6.3.5. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. By Drug Class
6.3.5.2.2. By Distribution Channel
6.3.5.2.3. By Application
7. North America Hereditary Angioedema Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Distribution Channel
7.2.3. By Application
7.2.4. By Country
7.3. North America: Country Analysis
7.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Distribution Channel
7.3.1.2.3. By Application
7.3.2. Mexico Hereditary Angioedema Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Distribution Channel
7.3.2.2.3. By Application
7.3.3. Canada Hereditary Angioedema Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Distribution Channel
7.3.3.2.3. By Application
8. South America Hereditary Angioedema Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Distribution Channel
8.2.3. By Application
8.2.4. By Country
8.3. South America: Country Analysis
8.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Distribution Channel
8.3.1.2.3. By Application
8.3.2. Argentina Hereditary Angioedema Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Distribution Channel
8.3.2.2.3. By Application
8.3.3. Colombia Hereditary Angioedema Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Distribution Channel
8.3.3.2.3. By Application
9. Middle East and Africa Hereditary Angioedema Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Distribution Channel
9.2.3. By Application
9.2.4. By Country
9.3. MEA: Country Analysis
9.3.1. South Africa Hereditary Angioedema Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Distribution Channel
9.3.1.2.3. By Application
9.3.2. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Distribution Channel
9.3.2.2.3. By Application
9.3.3. UAE Hereditary Angioedema Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Distribution Channel
9.3.3.2.3. By Application
9.3.4. Egypt Hereditary Angioedema Therapeutics Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Drug Class
9.3.4.2.2. By Distribution Channel
9.3.4.2.3. By Application
10. Market Dynamics
10.1. Drivers
10.2. Challenges
11. Market Trends & Developments
11.1. Recent Developments
11.2. Product Launches
11.3. Mergers & Acquisitions
12. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis
13. Porter?s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Product
14. Competitive Landscape
14.1. Shire plc
14.1.1. Business Overview
14.1.2. Company Snapshot
14.1.3. Products & Services
14.1.4. Current Capacity Analysis
14.1.5. Financials (In case of listed)
14.1.6. Recent Developments
14.1.7. SWOT Analysis
14.2. Sanofi SA
14.3. Pharming Healthcare Inc.
14.4. Attune Pharmaceuticals
14.5. Adverum Biotechnologies
14.6. Arrowhead Pharmaceuticals
14.7. Ionis Pharmaceuticals
14.8. BioCryst Pharmaceuticals Inc.
14.9. CSL Behring.
14.10. CENTOGENE N.V.
15. Strategic Recommendations
16. About Us & Disclaimer